Functional interaction between COL4A1/COL4A2 and SMAD3 risk loci for coronary artery disease

Atherosclerosis

Volumn 242, Issue 2, 2015, Pages 543-552

  Turner, Adam W ^a   Nikpay, Majid ^a   Silva, Anada ^a   Lau, Paulina ^a   Martinuk, Amy ^a   Linseman, Tara A ^a   Soubeyrand, Sebastien ^a   McPherson, Ruth ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Atherosclerosis; COL4A1; COL4A2; Coronary artery disease; Epistasis; SMAD3; TGF ; Type IV collagen

Indexed keywords

COLLAGEN TYPE 4; COLLAGEN TYPE 4A1; COLLAGEN TYPE 4A2; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; COL4A1 PROTEIN, HUMAN; COL4A2 PROTEIN, HUMAN; ENZYME INHIBITOR; SMAD3 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; GENE EXPRESSION; GENE INTERACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; AORTA; CELL LINE; CHEMISTRY; COHORT ANALYSIS; CYTOLOGY; EPISTASIS; FIBROBLAST; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

AORTA; CELL LINE; COHORT STUDIES; COLLAGEN TYPE IV; CORONARY ARTERY DISEASE; ENZYME INHIBITORS; EPISTASIS, GENETIC; FIBROBLASTS; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84939795786     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.08.008     Document Type: Article

References (59)

1. Schunkert H., König I.R., Kathiresan S., Reilly M.P., Assimes T.L., Holm H., Preuss M., Stewart A.F.R., Barbalic M., Gieger C., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat. Genet. 2011, 43:333-338.
2. Deloukas P., Kanoni S., Willenborg C., Farrall M., Assimes T.L., Thompson J.R., Ingelsson E., Saleheen D., Erdmann J., Goldstein B.A., et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat. Genet. 2013, 45:25-33.
3. Van Agtmael T., Bruckner-Tuderman L. Basement membranes and human disease. Cell Tissue Res. 2010, 339:167-188.
4. Kühn K. Basement membrane (type IV) collagen. Matrix Biol. 1995, 14:439-445.
5. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 2003, 3:422-433.
6. Tarasov K.V., Sanna S., Scuteri A., Strait J.B., Orrù M., Parsa A., Lin P.-I., Maschio A., Lai S., Piras M.G., et al. COL4A1 is associated with arterial stiffness by genome-wide association scan. Circ. Cardiovasc. Genet. 2009, 2:151-158.
7. Yamada Y., Kato K., Oguri M., Fujimaki T., Yokoi K., Matsuo H., Watanabe S., Metoki N., Yoshida H., Satoh K., et al. Genetic risk for myocardial infarction determined by polymorphisms of candidate genes in a Japanese population. J. Med. Genet. 2008, 45:216-221.
8. Van Agtmael T., Bailey M.A., Schlötzer-Schrehardt U., Craigie E., Jackson I.J., Brownstein D.G., Megson I.L., Mullins J.J. Col4a1 mutation in mice causes defects in vascular function and low blood pressure associated with reduced red blood cell volume. Hum. Mol. Genet. 2010, 19:1119-1128.
9. Sund M., Xie L., Kalluri R. The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis. APMIS 2004, 112:450-462.
10. Katsuda S., Okada L., Minamoto T., Oda Y., Matsui Y., Nakanishi I. Collagens in human atherosclerosis. Immunohistochemical analysis using collagen type-specific antibodies. Arter. Thromb. Vasc. Biol. 1992, 12:494-502.
11. Orr W.A., Lee M.Y., Lemmon J.A., Yurdagul A., Gomez M.F., Bortz P.D.S., Wamhoff B.R. Molecular mechanisms of collagen isotype-specific modulation of smooth muscle cell phenotype. Arterioscler. Thromb. Vasc. Biol. 2009, 29:225-231.
12. Bobik A. Transforming growth factor-βs and vascular disorders. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1712-1720.
13. Reifenberg K., Cheng F., Orning C., Crain J., Küpper I., Wiese E., Protschka M., Blessing M., Lackner K.J., Torzewski M. Overexpression of TGF-β1 in macrophages reduces and stabilizes atherosclerotic plaques in ApoE-deficient mice. PLoS One 2012, 7:e40990.
14. Owens G.A., Geisterfer A.A.T., Yang Y.W., Komoriya A. Transforming growth factor-β-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J. Cell Biol. 1988, 107:771-780.
15. Grainger D.J. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler. Thromb. Vasc. Biol. 2004, 24:399-404.
16. Lutgens E., Gijbels M., Smook M., Heeringa P., Gotwals P., Koteliansky V.E., Daemen M.J.A.P. Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 2002, 22:975-982.
17. Grainger D.J., Kemp P.R., Metcalfe J.C., Liu A.C., Lawn R.M. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat. Med. 1995, 1:74-79.
18. Tashiro H., Shimokawa H., Sadamatu K., Yamamoto K. Prognostic significance of plasma concentrations of transforming growth factor-beta in patients with coronary artery disease. Coron. Artery Dis. 2002, 13:139-143.
19. Mallat Z., Gojova A., Marchiol-Fournigault C., Esposito B., Kamate C., Merval R., Fradelizi D., Tedgui A. Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 2001, 89:930-934.
20. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature 2003, 4:577-584.
21. Derynck R., Akhurst R.J., Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 2001, 29:117-129.
22. Moustakas A., Souchelnytskyi S., Heldin C.H. Smad regulation in TGF-β signal transduction. J. Cell Sci. 2001, 114:4359-4369.
23. Miyazwa K., Shinozaki M., Hara T., Furuya T., Miyazono K. Two major Smad pathways in TGF-β superfamily signalling. Genes Cells 2002, 7:1191-1204.
24. Akhurst R.J., Hata A. Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 2012, 11:790-811.
25. Samani N.J., Erdmann J., Hall A.S., Hengstenberg C., Meitinger T., Braund P., Sc M., Wichmann H., Barrett J.H., König I.R., et al. Genomewide association analysis of coronary artery disease. N. Engl. J. Med. 2007, 357:443-453.
26. Madri J.A., Pratt B.M., Tucker A.M. Phenotypic modulation of endothelial cells by transforming growth factor depends upon the composition and organization of the extracellular matrix. J. Cell Biol. 1988, 106:1375-1384.
27. Janat M.F., Liau G. Transforming growth factor β1 is a powerful modulator of platelet-derived growth factor action in vascular smooth muscle cells. J. Cell. Physiol. 1992, 150:232-242.
28. Grande J.P. Transforming growth factor-beta 1 induces collagen IV gene expression in NIH-3T3 cells. Lab. Investig. 1993, 69:387-395.
29. Grande J.P., Melder D.C., Zinsmeister A.R. Modulation of collagen gene expression cytokines: Stimulatory effect of transforming growth factor-β1, with divergent effects of epidermal growth factor and tumour necrosis factor-α on collagen type I and collagen type IV. J. Lab. Clin. Med. 1997, 130:476-486.
30. Li J., Qu X., Ricardo S.D., Bertram J.F., Nikolic-Paterson D.J. Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am. J. Pathol. Am. Soc. Investig. Pathol. 2010, 177:1065-1071.
31. Ghosh S., Vivar J., Nelson C.P., Willenborg C., Segrè A.V., Mäkinen V.-P., Nikpay M., Erdmann J., Blankenberg S., O'Donnell C., et al. Systems Genetics Analysis of Genome-Wide Association Study Reveals Novel Associations Between Key Biological Processes and Coronary Artery Disease. Arterioscler. Thromb. Vasc. Biol. 2015, 35:1712-1722.
32. Schmidt C., Fischer G., Kadner H., Genersch E., Kühn K., Pöschl E. Differential effects of DNA-binding proteins on bidirectional transcription from the common promoter region of human collagen type IV genes COL4A1 and COL4A2. Biochim. Biophys. Acta 1993, 1174:1-10.
33. Fischer G., Schmidt C., Opitz J., Cully Z., Kühn K., Pöschl E. Identification of a novel sequence element in the common promoter region of human collagen type IV genes, involved in the regulation of divergent transcription. Biochem. J. 1993, 292:687-695.
34. Pollner R., Schmidt C., Fischer G., Kühn K., Pöschl E. Cooperative and competitive interactions of regulatory elements are involved in the control of divergent transcription of human Col4A1 and Col4A2 genes. FEBS Lett. Fed. Eur. Biochem. Soc. 1997, 405:31-36.
35. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A.R., Bender D., Maller J., Sklar P., de Bakker P.I.W., Daly M.J., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
36. Evangelou E., Ioannidis J.P.A. Meta-analysis methods for genome-wide association studies and beyond. Nat. Rev. Genet. Nat. Publ. Group 2013, 14:379-389.
37. Pollner R., Fischer G., Pöschl E., Kühn K. Regulation of divergent transcription of the genes coding for basement membrane type IV collagen. Ann. N. Y. Acad. Sci. 1990, 580:44-54.
38. Pöschl E., Pollner R., Kühn K. The genes for the alpha 1(IV) and alpha 2(IV) chains of human basement membrane collagen type IV are arranged head-to-head and separated by a bidirectional promoter of unique structure. EMBO J. 1988, 7:2687-2695.
39. Inman G.J., Francisco N.J., Callahan J.F., Harling J.D., Gaster L.M., Reith A.D., Laping N.J., Hill C.S. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 2002, 62:65-74.
40. Baugé C., Cauvard O., Leclercq S., Galéra P., Boumédiene K. Modulation of transforming growth factor beta signalling pathway genes by transforming growth factor beta in human osteoarthritic chondrocytes: involvement of Sp1 in both early and late response cells to transforming growth factor beta. Arthritis Res. Ther. Biomed. Cent. Ltd. 2011, 13:R23.
41. Poncelet A.-C., de Caestecker M.P., Schnaper H.W. The transforming growth factor-β/SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int. 1999, 56:1354-1365.
42. De Caestecker M.P., Piek E., Roberts A.B. Role of transforming growth factor-β signaling in cancer. J. Natl. Cancer Inst. 2000, 92:1388-1402.
43. Verrecchia F., Mauviel A. Transforming growth factor-β signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J. Investig. Dermatol. 2002, 118:211-215.
44. Verrecchia F., Chu M.L., Mauviel A. Identification of novel TGF-β/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J. Biol. Chem. 2001, 276:17058-17062.
45. Levy L., Hill C.S. Smad4 dependency defines two classes of transforming growth factor β (TGF-β) target genes and distinguishes TGF-β-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol. Cell Biol. 2005, 25:8108-8125.
46. Civelek M., Lusis A.J. Systems genetics approaches to understand complex traits. Nat. Rev. Genet. Nat. Publ. Group 2014, 15:34-48.
47. Ma L., Clark A.G., Keinan A. Gene-based testing of interactions in association studies of quantitative traits. PLoS Genet. 2013, 9:e1003321.
48. Sun X., Lu Q., Mukheerjee S., Crane P.K., Elston R., Ritchie M.D. Analysis pipeline for the epistasis search - statistical versus biological filtering. Front. Genet. 2014, 5:1-7.
49. Grande J.P., Warner G.M., Walker H.J., Yusufi A.N.K., Cheng J., Gray C.E., Kopp J.B., Nath K.A. TGF-β1 is an autocrine mediator of renal tubular epithelial cell growth and collagen IV production. Exp. Biol. Med. 2002, 227:171-181.
50. Kunico G.S., Alvarez R., Killen P.D., Neilson E.G., Paul D. Transforming growth factor-β modulation of the α1(IV) collagen gene in murine proximal tubular cells. Am. J. Physiol. Ren. Physiol. 1996, 271:F120-F125.
51. Silbiger S., Lei J., Ziyadeh F.N., Neugarten J., Baylis C., Chappell M.C., Yamaleyeva L.M., Westwood B.M., Physiol A.J., Integr R., et al. Estradiol reverses TGF-β1-stimulated type IV collagen gene transcription in murine mesangial cells mechanisms. Am. J. Physiol. Ren. Physiol. 1998, 274:F1113-F1118.
52. Zhang Y., Handley D., Kaplan T., Yu H., Bais A.S., Richards T., Pandit K.V., Zeng Q., Benos P.V., Friedman N., et al. High throughput determination of TGFβ1/SMAD3 targets in A549 lung epithelial cells. PLoS One 2011, 6:e20319.
53. Qin W., Chung A.C.K., Huang X.R., Meng X.-M., Hui D.S.C., Yu C.-M., Sung J.J.Y., Lan H.Y. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 2011, 22:1462-1474.
54. Zhou L., Wang L., Lu L., Jiang P., Sun H., Wang H. Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts. PLoS One 2012, 7:e33766.
55. Cushing L., Kuang P.P., Qian J., Shao F., Wu J., Little F., Thannickal V.J., Cardoso W.V., Lü J. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2011, 45:287-294.
56. Ekman M., Bhattachariya A., Dahan D., Uvelius B., Albinsson S., Swärd K. Mir-29 repression in bladder outlet obstruction contributes to matrix remodeling and altered stiffness. PLoS One 2013, 8:e82308.
57. Tseng Z.H., Vittinghoff E., Musone S.L., Lin F., Whiteman D., Pawlikowska L., Kwok P.-Y., Olgin J.E., Aouizerat B.E. Association of TGFBR2 polymorphism with risk of sudden cardiac arrest in patients with coronary artery disease. Heart Rhythm 2009, vol. 6:1745-1750. Elsevier Inc.
58. Adiguzel E., Ahmad P.J., Franco C., Bendeck M.P. Collagens in the progression and complications of atherosclerosis. Vasc. Med. 2009, 14:73-89.
59. Okada Y., Katsuda S. Collagen synthesis by cultured arterial smooth muscle cells during spontaneous phenotypic modulation. Acta Pathol. Jpn. 1990, 40:157-164.